PMID: 11932898Apr 5, 2002Paper

Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma

Cancer
Bo GronlundSvend A Engelholm

Abstract

Intravenous cytostatic agents as second-line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity. The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second-line treatment of epithelial ovarian carcinoma. This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC-IV epithelial ovarian carcinoma; first-line treatment with paclitaxel and a platinum analog; intravenous second-line treatment with topotecan 1.0 mg/m(2)/day for 5 days, every 3 weeks or paclitaxel (175 mg/m(2)) and carboplatin (AUC 5), every 3 weeks. One hundred two patients fulfilled the inclusion criteria receiving topotecan (n = 57) or paclitaxel-carboplatin (n = 45) because of refractory or recurrent disease. The patients' age at start of second-line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7-64.3) and 69.5 years (range, 65.1-77.2), resp...Continue Reading

References

Mar 1, 1986·American Journal of Obstetrics and Gynecology·R YancikJ W Yates
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 15, 1994·Cancer·R C Park
Apr 1, 1993·Scientific American·S J OlshanskyC K Cassel
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinH E Lambert
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G J RustinH E Lambert
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Mar 14, 1998·Journal of Cancer Research and Clinical Oncology·M Markman
Jan 23, 1999·Obstetrics and Gynecology·K A OrielP L Remington
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E A EisenhauerJ P Neijt
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S BerekP H Willemse
Aug 10, 2000·Drugs & Aging·R E van Rijswijk, J B Vermorken
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen

❮ Previous
Next ❯

Citations

Nov 11, 2003·Critical Reviews in Oncology/hematology·Deborah McCaffrey Boyle
Jan 22, 2004·Critical Reviews in Oncology/hematology·Sandro Pignata, Jan B Vermorken
Aug 24, 2012·The Oncologist·Min Y TeoStuart M Lichtman
Jul 24, 2003·Drugs & Aging·Veena JohnStuart Lichtman
Mar 16, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J E KurtzUNKNOWN Gynecologic Cancer Intergroup
Oct 6, 2005·Cancer Investigation·Tarun Wasil, Stuart M Lichtman
May 30, 2012·Obstetrics and Gynecology Clinics of North America·Clare Reade, Laurie Elit
Jan 12, 2016·Hereditary Cancer in Clinical Practice·Agnieszka SynowiecCezary Szczylik
Oct 6, 2009·Gynecologic Oncology·Flora VernooijA Peter M Heintz
Apr 18, 2009·Critical Reviews in Oncology/hematology·Damien UrbanRaphael Catane
Nov 26, 2008·Seminars in Oncology·William P Tew, Stuart M Lichtman
May 15, 2007·Journal of the American Medical Directors Association·Susan M Richman, Margaret A Drickamer
Sep 29, 2006·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Farah Diba BegumClaus K Høgdall
Dec 3, 2014·Gynecologic Oncology·William P Tew, Gini F Fleming
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine BouchardyGeorges Vlastos
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William E WinterUNKNOWN Gynecologic Oncology Group Study
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rosemary D CressSharon L Campleman
Mar 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine D CrewDawn L Hershman
Jun 1, 2004·The Oncologist·Richard T PensonThomas J Lynch
Feb 27, 2014·The Oncologist·Marie LaurentUNKNOWN ELCAPA Study Group
Apr 5, 2019·Current Opinion in Obstetrics & Gynecology·Yoshio Yoshida
May 21, 2015·American Society of Clinical Oncology Educational Book·Linda R DuskaKathleen N Moore
May 30, 2013·American Society of Clinical Oncology Educational Book·G FreyerK N Moore
Jan 1, 2014·International Scholarly Research Notices·Mohammad EzzatiShohreh Shahabi
Jan 18, 2019·JCO Clinical Cancer Informatics·Liz Salmi, Jeremy L Warner
Dec 14, 2018·Archives of Gynecology and Obstetrics·Salvatore Giovanni VitaleAntonio Simone Laganà
Jan 24, 2007·Cancer Control : Journal of the Moffitt Cancer Center·Ulrich WeddingKlaus Höffken
Nov 4, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O TrédanUNKNOWN Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

© 2022 Meta ULC. All rights reserved